At the end of last year, EUROIMMUN and Xpedite Diagnostics announced the start of a strategic partnership. Now the time has come: EUROArray SwiftX-traction is a rapid extraction procedure enabling the isolation of pathogen DNA for further analysis using EUROIMMUN’s EUROArrays. It has been especially developed for EUROIMMUN and is now approved worldwide for diagnostic […]
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency announced their positive opinion on the marketing authorisation of lecanemab (monoclonal anti-beta-amyloid antibody; trade name: Leqembi from Eisai and Biogen) in the European Union for the treatment of early Alzheimer’s disease in Europe. In 2023, the drug
Press release October 2nd 2024 APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is
Press release Lübeck, 25 April 2024 Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN’s extensive distribution network and support infrastructure with ALPCO-GeneProof’s
CSF diagnostics means the analysis of the fluid that circulates in the brain and the bone marrow (liquor cerebrospinalis, cerebrospinal fluid). It is a valuable tool to detect acute or chronic inflammatory processes in the central nervous system (CNS). The cause of such often severe diseases of the CNS may be infections with bacteria (e.g.
